Literature DB >> 31985040

Frizzled-4 is required for normal bone acquisition despite compensation by Frizzled-8.

Priyanka Kushwaha1, Soohyun Kim1, Gabrielle E Foxa2, Megan N Michalski2, Bart O Williams2, Ryan E Tomlinson3, Ryan C Riddle1,4.   

Abstract

The activation of the Wnt/β-catenin signaling pathway is critical for skeletal development but surprisingly little is known about the requirements for the specific frizzled (Fzd) receptors that recognize Wnt ligands. To define the contributions of individual Fzd proteins to osteoblast function, we profiled the expression of all 10 mammalian receptors during calvarial osteoblast differentiation. Expression of Fzd4 was highly upregulated during in vitro differentiation and therefore targeted for further study. Mice lacking Fzd4 in mature osteoblasts had normal cortical bone structure but reduced cortical tissue mineral density and also exhibited an impairment in the femoral trabecular bone acquisition that was secondary to a defect in the mineralization process. Consistent with this observation, matrix mineralization, markers of osteoblastic differentiation, and the ability of Wnt3a to stimulate the accumulation of β-catenin were reduced in cultures of calvarial osteoblasts deficient for Fzd4. Interestingly, Fzd4-deficient osteoblasts exhibited an increase in the expression of Fzd8 both in vitro and in vivo, which suggests that the two receptors may exhibit overlapping functions. Indeed, ablating a single Fzd8 allele in osteoblast-specific Fzd4 mutants produced a more severe effect on bone acquisition. Taken together, our data indicate that Fzd4 is required for normal bone development and mineralization despite compensation from Fzd8.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  Frizzled-4; Frizzled-8; Wnt signaling; bone; osteoblast

Mesh:

Substances:

Year:  2020        PMID: 31985040      PMCID: PMC7382978          DOI: 10.1002/jcp.29563

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  50 in total

Review 1.  Guidelines for assessment of bone microstructure in rodents using micro-computed tomography.

Authors:  Mary L Bouxsein; Stephen K Boyd; Blaine A Christiansen; Robert E Guldberg; Karl J Jepsen; Ralph Müller
Journal:  J Bone Miner Res       Date:  2010-07       Impact factor: 6.741

Review 2.  International Union of Pharmacology. XLVI. G protein-coupled receptor list.

Authors:  Steven M Foord; Tom I Bonner; Richard R Neubig; Edward M Rosser; Jean-Phillipe Pin; Anthony P Davenport; Michael Spedding; Anthony J Harmar
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

3.  WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta.

Authors:  Christine M Laine; Kyu Sang Joeng; Philippe M Campeau; Riku Kiviranta; Kati Tarkkonen; Monica Grover; James T Lu; Minna Pekkinen; Maija Wessman; Terhi J Heino; Vappu Nieminen-Pihala; Mira Aronen; Tero Laine; Heikki Kröger; William G Cole; Anna-Elina Lehesjoki; Lisette Nevarez; Deborah Krakow; Cynthia J R Curry; Daniel H Cohn; Richard A Gibbs; Brendan H Lee; Outi Mäkitie
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

Review 4.  The complex world of WNT receptor signalling.

Authors:  Christof Niehrs
Journal:  Nat Rev Mol Cell Biol       Date:  2012-11-15       Impact factor: 94.444

Review 5.  Frizzled Receptors in Development and Disease.

Authors:  Yanshu Wang; Hao Chang; Amir Rattner; Jeremy Nathans
Journal:  Curr Top Dev Biol       Date:  2016-01-27       Impact factor: 4.897

6.  Multisystem study of 20 older adults with Williams syndrome.

Authors:  Elizabeth M Cherniske; Thomas O Carpenter; Cheryl Klaiman; Eytan Young; Joel Bregman; Karl Insogna; Robert T Schultz; Barbara R Pober
Journal:  Am J Med Genet A       Date:  2004-12-15       Impact factor: 2.802

7.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.

Authors:  W Balemans; N Patel; M Ebeling; E Van Hul; W Wuyts; C Lacza; M Dioszegi; F G Dikkers; P Hildering; P J Willems; J B G M Verheij; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  J Med Genet       Date:  2002-02       Impact factor: 6.318

8.  Mutations in WNT1 cause different forms of bone fragility.

Authors:  Katharina Keupp; Filippo Beleggia; Hülya Kayserili; Aileen M Barnes; Magdalena Steiner; Oliver Semler; Björn Fischer; Gökhan Yigit; Claudia Y Janda; Jutta Becker; Stefan Breer; Umut Altunoglu; Johannes Grünhagen; Peter Krawitz; Jochen Hecht; Thorsten Schinke; Elena Makareeva; Ekkehart Lausch; Tufan Cankaya; José A Caparrós-Martín; Pablo Lapunzina; Samia Temtamy; Mona Aglan; Bernhard Zabel; Peer Eysel; Friederike Koerber; Sergey Leikin; K Christopher Garcia; Christian Netzer; Eckhard Schönau; Victor L Ruiz-Perez; Stefan Mundlos; Michael Amling; Uwe Kornak; Joan Marini; Bernd Wollnik
Journal:  Am J Hum Genet       Date:  2013-03-14       Impact factor: 11.025

9.  Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition.

Authors:  Ryan C Riddle; Cassandra R Diegel; Julie M Leslie; Kyle K Van Koevering; Marie-Claude Faugere; Thomas L Clemens; Bart O Williams
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

Review 10.  Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System.

Authors:  Marco Ponzetti; Nadia Rucci
Journal:  Front Endocrinol (Lausanne)       Date:  2019-04-18       Impact factor: 5.555

View more
  2 in total

1.  Comprehensive analysis of lncRNA-miRNA-mRNA networks during osteogenic differentiation of bone marrow mesenchymal stem cells.

Authors:  Jialin Liu; Yuan Yao; Jinyong Huang; Hao Sun; Yixuan Pu; Mengting Tian; Meijie Zheng; Huiyu He; Zheng Li
Journal:  BMC Genomics       Date:  2022-06-07       Impact factor: 4.547

2.  LINC01119 negatively regulates osteogenic differentiation of mesenchymal stem cells via the Wnt pathway by targeting FZD4.

Authors:  Hongwei Gao; Hui Dong; Jiachun Zheng; Xufeng Jiang; Mingzhi Gong; Le Hu; Jinshan He; Yongxiang Wang
Journal:  Stem Cell Res Ther       Date:  2022-01-29       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.